Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem

 
• By Brenda Sandburg
  
Drug competition
Patent system is not being misused to unjustifiably delay drug competition, biopharma reps tell USPTO and FDA • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership